Not recruiting
Type 2 diabetes mellitus
Not recruitingEvaluation of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients with High Cardiovascular Risk
Registered drugNo placebo
Evaluation of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients with High Cardiovascular Risk
Registered drugNo placebo
- Disease:Type 2 diabetes mellitus
- Substances:DulaglutideTirzepatide
Countries:
Hungary
Hungary- Participants:18–64 years · 65+ years
- Substances:Dulaglutide
